CERECOR - Trademark Details
Status: 733 - Fourth Extension - Granted
Serial Number
88424859
Word Mark
CERECOR
Status
733 - Fourth Extension - Granted
Status Date
2021-12-01
Filing Date
2019-05-10
Mark Drawing
3000 - Illustration: Drawing or design which also includes word(s)/ letter(s)/number(s)
Typeset
Design Searches
011102 - Partial moons, including half moons and crescent moons.
Published for Opposition Date
2019-10-08
Attorney Name
Law Office Assigned Location Code
L70
Employee Name
BUTLER, MIDGE FAE
Statements
Indication of Colors claimed
Color is not claimed as a feature of the mark.
Description of Mark
The mark consists of a crescent shaped figure with various lines throughout and the word "CERECOR" written within the crescent with the points of the crescent falling on the "ER" of the word.
Goods and Services
Pharmaceutical preparations for the prevention and treatment of disorders and diseases in or affecting the central nervous system; Pharmaceutical preparations for the treatment of the brain, central nervous system, and psychiatric and neurological diseases and disorders; Pharmaceutical preparations and substances for the prevention and treatment of major depressive disorder, mood disorder, psychosis, anxiety, epilepsy, sclerosis, porphyries, stroke, Huntington's disease, insomnia, Parkinson's disease, cognitive impairment; Pharmaceutical preparations for the treatment of ectoparasites, such as head lice; Steroids; Pharmaceutical preparations containing prednisolone for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculoskeletal system, the genitourinary system; Pharmaceutical preparations containing prednisolone for the treatment of inflammatory disorders; Pharmaceutical preparations containing prednisolone for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Medical delivery apparatus, namely, a valved holding chamber sold empty for use with metered dose inhalers; Cephalosporins; Antibiotics; Pharmaceutical preparations for the treatment of reflux, esophagitis, GERD (Gastro-Esophageal Reflux Disease), dyspepsia, heartburn, acid regurgitation, pyrosis, epigastric pain, irritative cough and dysphonia; Oral modified release, extended release, and/or sustained release pharmaceutical preparations for the drug carbinoxamine, a pharmaceutically acceptable salt thereof and/or carbinoxamine polistirex, intended for the treatment of seasonal and perennial allergic rhinitis, and other approved uses; Vitamin, mineral and fluoride preparations for human medical or nutritional uses; Nutritional preparation in the nature of nutritional supplement containing vitamins and fluoride; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral formulation of D-galactose for the treatment of phosphoglucomutase 1 (PGM1) deficiency (PGM1-CDG), oral formulation of D-mannose for the treatment of Mannose Phosphate Isomerase (MPI) deficiency (MPI-CDG), oral formulation of L-fucose for the treatment of Leukocyte Adhesion Deficiency Type II (LADII) (SLC35C1-CDG), nucleotide prodrug for the treatment of Deoxyguanosine Kinase (DGUOK) deficiency; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral formulations for the treatment of congenital disorders of glycosylation; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral nucleotide replacements for the treatment of Myelodysplastic Syndromes; Pharmaceutical preparations and substances for the treatment of neurogenic orthostatic hypotension (nOH) associated with neurodegenerative diseases such as Parkinson's Disease, Multiple Systems Atrophy, and Pure Autonomic Failure; Transmembrane AMPA receptor regulatory proteins (TARPs) for use as anticonvulsant agents and to modulate neurotransmission in patients with epilepsy; Oral neuro-selective adjunctive medications; Selective kappa opioid receptor (KOR) antagonist for the treatment of major depressive disorder (MDD) and for substance use disorders
Classification Information
International Class
005 - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. - Pharmaceutical, veterinary and sanitary preparations; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes
006, 018, 044, 046, 051, 052
Class Status Code
6 - Active
Class Status Date
2019-05-25
Primary Code
005
Current Trademark Owners
Party Name
Party Type
21 - 1st New Owner After Publication
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Trademark Owner History
Party Name
Party Type
21 - 1st New Owner After Publication
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Party Name
Party Type
20 - Owner at Publication
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Party Name
Party Type
10 - Original Applicant
Legal Entity Type
03 - Corporation
Address
Please log in with your Justia account to see this address.
Correspondences
Name
Paul J. Kennedy
Address
Please log in with your Justia account to see this address.
Prior Registrations
Relationship Type | Reel Number |
Prior Registration | 4822297 |
Trademark Events
Event Date | Event Description |
2019-05-14 | NEW APPLICATION ENTERED IN TRAM |
2019-05-25 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
2019-05-28 | NOTICE OF DESIGN SEARCH CODE E-MAILED |
2019-07-25 | ASSIGNED TO EXAMINER |
2019-08-01 | PRIORITY ACTION WRITTEN |
2019-08-01 | PRIORITY ACTION E-MAILED |
2019-08-01 | NOTIFICATION OF PRIORITY ACTION E-MAILED |
2019-08-30 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
2019-08-30 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
2019-08-30 | TEAS/EMAIL CORRESPONDENCE ENTERED |
2019-09-03 | APPROVED FOR PUB - PRINCIPAL REGISTER |
2019-09-05 | ASSIGNED TO LIE |
2019-09-18 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
2019-10-08 | PUBLISHED FOR OPPOSITION |
2019-10-08 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
2019-12-03 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
2020-04-28 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
2020-04-28 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
2020-04-28 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
2020-04-28 | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
2020-04-28 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
2020-04-28 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
2020-05-27 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
2020-05-27 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
2020-06-02 | TEAS WITHDRAWAL OF ATTORNEY RECEIVED |
2020-06-02 | WITHDRAWAL OF ATTORNEY GRANTED |
2020-06-02 | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
2020-06-02 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
2020-06-02 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
2020-06-02 | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
2020-06-02 | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
2020-06-03 | TEAS EXTENSION RECEIVED |
2020-06-03 | EXTENSION 1 FILED |
2020-06-03 | EXTENSION 1 GRANTED |
2020-06-05 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2020-12-02 | TEAS EXTENSION RECEIVED |
2020-12-02 | EXTENSION 2 FILED |
2020-12-07 | EXTENSION 2 GRANTED |
2020-12-08 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2021-05-20 | TEAS EXTENSION RECEIVED |
2021-05-20 | EXTENSION 3 FILED |
2021-05-20 | EXTENSION 3 GRANTED |
2021-05-22 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
2021-09-22 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
2021-12-01 | TEAS EXTENSION RECEIVED |
2021-12-01 | EXTENSION 4 FILED |
2021-12-01 | EXTENSION 4 GRANTED |
2021-12-03 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |